# Translarna™ (ataluren) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ataluren

> Translarna™ (ataluren), sponsored by PTC THERAPEUTICS, INC. (PTCT): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Translarna™ (ataluren) |
| Codes | PTC124 |
| Sponsor | PTC THERAPEUTICS, INC. (PTCT) https://sec-api.dev/companies/ptct/catalysts |
| Indications | nmdmd, [Duchenne Muscular Dystrophy](https://sec-api.dev/indications/duchenne-muscular-dystrophy) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jul 2024: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: nmDMD.
- First seen 2025-02-27, last confirmed 2026-02-19.
- SEC Form 10-K (accession 0001104659-26-017575): "Based on feedback from the FDA, we re-submitted the NDA in July 2024, based on the results from Study 041 and from our international drug registry study for nmDMD patients receiving Translarna." https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-017575): "Based on feedback from the FDA, the Company re-submitted the NDA in July 2024, based on the results from Study 041 and from its international drug registry study for nmDMD patients receiving Translarna." https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm
- SEC Form 10-Q (accession 0001070081-25-000028): "Based on feedback from the FDA, the Company resubmitted the NDA in July 2024, based on the results from Study 041 and from the Company's international drug registry study for nmDMD patients receiving Translarna." https://www.sec.gov/Archives/edgar/data/1070081/000107008125000028/tmb-20250930x10q.htm
- SEC Form 10-Q (accession 0001070081-25-000028): "Based on feedback from the FDA, we resubmitted the NDA in July 2024, based on the results from Study 041 and from our international drug registry study for nmDMD patients receiving Translarna." https://www.sec.gov/Archives/edgar/data/1070081/000107008125000028/tmb-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010796): "Based on feedback from the FDA, the Company resubmitted the NDA in July 2024, based on the results from Study 041 and from the Company's international drug registry study for nmDMD patients receiving Translarna." https://www.sec.gov/Archives/edgar/data/1070081/000155837025010796/tmb-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010796): "Based on feedback from the FDA, we resubmitted the NDA in July 2024, based on the results from Study 041 and from our international drug registry study for nmDMD patients receiving Translarna." https://www.sec.gov/Archives/edgar/data/1070081/000155837025010796/tmb-20250630x10q.htm
- SEC Form 10-Q (accession 0001070081-25-000019): "Based on feedback from the FDA, we resubmitted the NDA in July 2024, based on the results from Study 041 and from our international drug registry study for nmDMD patients receiving Translarna." https://www.sec.gov/Archives/edgar/data/1070081/000107008125000019/tmb-20250331x10q.htm
- SEC Form 10-K (accession 0001070081-25-000012): "Based on feedback from the FDA, we re-submitted the NDA in July 2024, based on the results from Study 041 and from our international drug registry study for nmDMD patients receiving Translarna." https://www.sec.gov/Archives/edgar/data/1070081/000107008125000012/tmb-20241231x10k.htm
- SEC Form 10-K (accession 0001070081-25-000012): "In July 2024, we re-submitted the NDA to the FDA for Translarna for the treatment of nmDMD." https://www.sec.gov/Archives/edgar/data/1070081/000107008125000012/tmb-20241231x10k.htm
- SEC Form 10-K (accession 0001070081-25-000012): "Based on feedback from the FDA, the Company re-submitted the NDA in July 2024, based on the results from Study 041 and from the Company's international drug registry study for nmDMD patients receiving Translarna." https://www.sec.gov/Archives/edgar/data/1070081/000107008125000012/tmb-20241231x10k.htm

### Oct 2024: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-03-03, last confirmed 2026-02-26.
- SEC Form 10-K (accession 0001104659-26-020112): "It remains unclear if the data will lead to FDA approval of Translarna, for which the company resubmitted the NDA in October 2024." https://www.sec.gov/Archives/edgar/data/1710072/000110465926020112/ewtx-20251231x10k.htm
- SEC Form 10-K (accession 0001558370-25-002006): "It remains unclear if the data will lead to FDA approval of Translarna, for which the company resubmitted the NDA in October 2024." https://www.sec.gov/Archives/edgar/data/1710072/000155837025002006/ewtx-20241231x10k.htm

### February 10, 2026: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Duchenne Muscular Dystrophy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT01247207 (Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-02-10 (ACTUAL); Lead Sponsor PTC Therapeutics; Results First Posted 2026-10-08." https://clinicaltrials.gov/study/NCT01247207

## Same indication

- [ELEVIDYS (delandistrogene moxeparvovec)](https://sec-api.dev/pdufa/delandistrogene-moxeparvovec) (SRPT)
- [Fordadistrogene movaparvovec](https://sec-api.dev/pdufa/fordadistrogene-movaparvovec) (PFE)
- [Pgn-edo51](https://sec-api.dev/pdufa/pgn-edo51) (PEPG)
- [RGX-202](https://sec-api.dev/pdufa/rgx-202) (RGNX)
- [SAT-3247](https://sec-api.dev/pdufa/sat-3247) (MSLE)
- [Sevasemten](https://sec-api.dev/pdufa/sevasemten) (EWTX)
- [Wve-n531](https://sec-api.dev/pdufa/wve-n531) (WVE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ataluren.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Translarna™ (ataluren) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ataluren

```bibtex
@misc{secapidev_pdufa_ataluren_20261116,
  title        = {Translarna™ (ataluren) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ataluren}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ataluren_20261116","title":"Translarna™ (ataluren) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ataluren","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
